[
  {
    "ts": null,
    "headline": "Idiopathic Pulmonary Fibrosis Research Report 2025-2035: Market Led by Roche, Pliant Therapeutics, Bristol-Myers Squibb, and Vicore as Next-Gen Antifibrotics and Targeted Therapies Drive Innovation",
    "summary": "Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease marked by gradual scarring, limiting lung function. The exact cause is unknown, but it combines genetic and environmental factors. With symptoms like shortness of breath and fatigue, IPF lacks a cure, necessitating effective treatments. Increasing cases, driven by aging populations and better diagnosis, spur R&D on new therapies. Companies like Hoffmann-La Roche and Bristol-Myers Squibb innovate with targeted and biologic therapie",
    "url": "https://finnhub.io/api/news?id=7fee2b22726edc24f120e3dfc39b438f462cfbea96b5426fcb043c0538935b48",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763478360,
      "headline": "Idiopathic Pulmonary Fibrosis Research Report 2025-2035: Market Led by Roche, Pliant Therapeutics, Bristol-Myers Squibb, and Vicore as Next-Gen Antifibrotics and Targeted Therapies Drive Innovation",
      "id": 137538423,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease marked by gradual scarring, limiting lung function. The exact cause is unknown, but it combines genetic and environmental factors. With symptoms like shortness of breath and fatigue, IPF lacks a cure, necessitating effective treatments. Increasing cases, driven by aging populations and better diagnosis, spur R&D on new therapies. Companies like Hoffmann-La Roche and Bristol-Myers Squibb innovate with targeted and biologic therapie",
      "url": "https://finnhub.io/api/news?id=7fee2b22726edc24f120e3dfc39b438f462cfbea96b5426fcb043c0538935b48"
    }
  },
  {
    "ts": null,
    "headline": "Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?",
    "summary": "Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at RXRX stock and its latest earnings.",
    "url": "https://finnhub.io/api/news?id=07ff206a122b4ea7729f18bab5dce1dcb5e21779ca9765eebb0e4c3588fb62de",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763460874,
      "headline": "Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?",
      "id": 137538047,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412857430/image_1412857430.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at RXRX stock and its latest earnings.",
      "url": "https://finnhub.io/api/news?id=07ff206a122b4ea7729f18bab5dce1dcb5e21779ca9765eebb0e4c3588fb62de"
    }
  },
  {
    "ts": null,
    "headline": "Why Bristol-Myers Squibb Remains Undervalued In 2025",
    "summary": "Discover why Bristol-Myers Squibb stands out in Big Pharma with strong sales growth and a solid dividend yield.",
    "url": "https://finnhub.io/api/news?id=ef870d0978205ddbda040a9c799af982910929083ae52e5bd46e2219a463e9b2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763457986,
      "headline": "Why Bristol-Myers Squibb Remains Undervalued In 2025",
      "id": 137537841,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/937153960/image_937153960.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Discover why Bristol-Myers Squibb stands out in Big Pharma with strong sales growth and a solid dividend yield.",
      "url": "https://finnhub.io/api/news?id=ef870d0978205ddbda040a9c799af982910929083ae52e5bd46e2219a463e9b2"
    }
  },
  {
    "ts": null,
    "headline": "The Market Is Crashing: Here Is What I Am Buying",
    "summary": "The Market Is Crashing: Here Is What I Am Buying",
    "url": "https://finnhub.io/api/news?id=eb0a8d79ee9bdff67781753e01c59bbe70a84d1c622461a6f94228ae1ee5cff5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763456100,
      "headline": "The Market Is Crashing: Here Is What I Am Buying",
      "id": 137537699,
      "image": "",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=eb0a8d79ee9bdff67781753e01c59bbe70a84d1c622461a6f94228ae1ee5cff5"
    }
  },
  {
    "ts": null,
    "headline": "[Latest] Global NUT Midline Carcinoma Treatment Market Size/Share Worth USD 93.34 Billion by 2034 at a 15.26% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT)",
    "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global NUT Midline Carcinoma Treatment Market size & share revenue was valued at approximately USD 22.67 Billion in 2024 and is expected to reach USD 26.13 Billion in 2025 and is expected to reach around USD 93.34 Billion by 2034, at a CAGR of 15.26% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Merck & Co.",
    "url": "https://finnhub.io/api/news?id=10e4f4a6238a1404fc41578349c3fefd3a6088b212b55815a92542bbea1bf70a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763454600,
      "headline": "[Latest] Global NUT Midline Carcinoma Treatment Market Size/Share Worth USD 93.34 Billion by 2034 at a 15.26% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT)",
      "id": 137538307,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global NUT Midline Carcinoma Treatment Market size & share revenue was valued at approximately USD 22.67 Billion in 2024 and is expected to reach USD 26.13 Billion in 2025 and is expected to reach around USD 93.34 Billion by 2034, at a CAGR of 15.26% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Merck & Co.",
      "url": "https://finnhub.io/api/news?id=10e4f4a6238a1404fc41578349c3fefd3a6088b212b55815a92542bbea1bf70a"
    }
  },
  {
    "ts": null,
    "headline": "Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q3",
    "summary": "Wrapping up Q3 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Bristol-Myers Squibb (NYSE:BMY) and its peers.",
    "url": "https://finnhub.io/api/news?id=ff0d1d10dc5cbd32253c9fa28f3c2be7dff850fe38ef7c3a0615f02268ac960f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763436809,
      "headline": "Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q3",
      "id": 137538425,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Wrapping up Q3 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Bristol-Myers Squibb (NYSE:BMY) and its peers.",
      "url": "https://finnhub.io/api/news?id=ff0d1d10dc5cbd32253c9fa28f3c2be7dff850fe38ef7c3a0615f02268ac960f"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers",
    "summary": "PRINCETON, N.J., November 18, 2025--Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers",
    "url": "https://finnhub.io/api/news?id=e149cfcb423e8e22ff15fbb18e74d7b729c451ed2799037383ba1d14a7ac2f8d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763436780,
      "headline": "Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers",
      "id": 137522919,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., November 18, 2025--Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers",
      "url": "https://finnhub.io/api/news?id=e149cfcb423e8e22ff15fbb18e74d7b729c451ed2799037383ba1d14a7ac2f8d"
    }
  }
]